We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Critical Gene Altered in Numerous Fibroadenoma Patients

By LabMedica International staff writers
Posted on 13 Aug 2014
Advanced DNA sequencing technologies have been used to identify a critical gene that was repeatedly disrupted in nearly 60% of fibroadenoma cases.

Frequently discovered in clinical workups for breast cancer diagnosis and during routine breast cancer screening, clinicians often face the challenge of distinguishing fibroadenomas from breast cancer.

A multidisciplinary team of scientists from the National Cancer Center Singapore (Singapore) and their colleagues studies a total of 98 fibroadenoma tumors of which 12 were from fresh-frozen tumors and a further 86 were from archival formalin-fixed paraffin-embedded (FFPE) samples. More...
Tumors and whole blood were obtained from patients undergoing surgical excision of fibroadenoma.

The team used a variety of molecular techniques including a technique called laser capture microdissection (LCM). Fresh-frozen fibroadenomas were embedded in optimal cutting temperature (OCT) compound and 8 μm-thick sections were cut using a microtome cryostat. Stained slides were then loaded onto the laser capture microscope stage. The ArcturusXT Laser Capture Microdissection (LCM) System and a Capsure Macro LCM cap (Life Technologies, Grand Island, NY, USA) were then placed automatically over the chosen area of the tissue.

By analyzing all the protein-coding genes in a panel of fibroadenomas from the patients, the team identified frequent mutations in a gene called Mediator Complex Subunit 12 (MED12) in a remarkable 60% of fibroadenomas. Like most breast tumors including breast cancers, fibroadenomas consist of a mixed population of different cell types, called epithelial cells and stromal cells. However, unlike breast cancers where the genetic abnormalities arise from the epithelial cells, the scientists showed that the pivotal MED12 mutations in fibroadenomas are found in the stromal cells using the LCM technique.

Patrick Tan, MD, PhD, a professor and a lead author of the study said, “It is amazing that these common breast tumors can be caused by such a precise disruption in a single gene. Our findings show that even common diseases can have a very exact genetic basis. Importantly, now that we know the cause of fibroadenoma, this study can have many potential applications. For example, measuring the MED12 gene in breast lumps may help clinicians to distinguish fibroadenomas from other types of breast cancer. Drugs targeting the MED12 pathway may also be useful in patients with multiple and recurrent fibroadenomas as this could help patients avoid surgery and relieve anxiety.” The study was published on July 20, 2014, in the journal Nature Genetics.

Related Links:

National Cancer Center Singapore
Life Technologies, Grand Island



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Gastrointestinal Panel
Xpert® GI Panel
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.